Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study

设为首页

收藏本站

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Readers' Guide

Opening Hours
Collections
Help Via Email

Publications

Electronic Information Resources

Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study

详细信息查看全文

作者：L. Cai ; J. Gu ; J. Zheng ; M. Zheng ; G. Wang ; L.-Y. Xi ; F. Hao ; X.-M. Liu ; Q.-N. Sun ; Y. Wang ; W. Lai ; H. Fang ; Y.-T. Tu ; Q. Sun ; J. Chen ; X.-H. Gao ; Y. Gu ; H.D. Teixeira ; J.-Z. Zhang and M.M. Okun
刊名：Journal of the European Academy of Dermatology and Venereology
出版年：2017
出版时间：January 2017
年：2017
卷：31
期：1
页码：89-95
全文大小：176K
ISSN：1468-3083

文摘

This phase 3 trial is the first to evaluate the efficacy and safety of treatment with the systemic TNF-α inhibitor, adalimumab, for Chinese patients with moderate-to-severe plaque psoriasis.